---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016874"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:59:07.986557+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Erasca Q2 net loss $35.6M; cash $390.8M; pipeline on track for H2 catalysts

## Summary
- Net loss of $35.6M ($0.30 per share) vs $28.2M ($1.20) year ago; R&D expenses $27.5M, G&A $8.4M.
- Cash, equivalents, and marketable securities $390.8M as of June 30, 2022; expected to fund operations into H2 2024.
- Initial Phase 1b monotherapy data for ERAS-007 (HERKULES-1) and Phase 1 data for ERAS-601 (FLAGSHP-1) expected H2 2022.
- IND filing for CNS-penetrant KRAS G12C inhibitor ERAS-3490 in KRAS G12C-mutant NSCLC expected H2 2022.
- Entered clinical trial collaboration with Eli Lilly to evaluate cetuximab + ERAS-601; expanded leadership and board.

## SEC filing metadata
- accession: 0000950170-22-016874
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017022016874/0000950170-22-016874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017022016874/eras-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016874
- JSON: https://secwatch.observer/filing/0000950170-22-016874.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.